

# **Clinical significance of *ASXL2* and *ZBTB7A* mutations and C-terminally truncated *RUNX1-RUNX1T1* expression in AML patients with t(8;21) enrolled in the JALSG AML201 study**

Naomi Kawashima<sup>1,\*</sup>, Akimi Akashi<sup>1,\*</sup>, Yasunobu Nagata<sup>2,3,\*</sup>, Rika Kihara<sup>1,\*</sup>, Yuichi Ishikawa<sup>1,\*</sup>, Norio Asou<sup>4</sup>, Shigeki Ohtake<sup>5</sup>, Shuichi Miyawaki<sup>6</sup>, Toru Sakura<sup>7</sup>, Yukiyasu Ozawa<sup>8</sup>, Noriko Usui<sup>9</sup>, Heiwa Kanamori<sup>10</sup>, Yoshikazu Ito<sup>11</sup>, Kiyotoshi Imai<sup>12</sup>, Youko Suehiro<sup>13</sup>, Kunio Kitamura<sup>14</sup>, Emiko Sakaida<sup>15</sup>, Akihiro Takeshita<sup>16</sup>, Hitoshi Suzushima<sup>17</sup>, Tomoki Naoe<sup>18</sup>, Itaru Matsumura<sup>19</sup>, Yasushi Miyazaki<sup>20</sup>, Seishi Ogawa<sup>2</sup>, and Hitoshi Kiyoi<sup>1</sup> for the Japan Adult Leukemia Study Group (JALSG)

<sup>1</sup> Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>2</sup> Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan

<sup>3</sup> Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA

<sup>4</sup> Department of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan

<sup>5</sup> Kanazawa University, Kanazawa, Japan

<sup>6</sup> Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan

<sup>7</sup> Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

<sup>8</sup> Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

<sup>9</sup> Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

<sup>10</sup> Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

<sup>11</sup> Department of Hematology, Tokyo Medical University, Tokyo, Japan

<sup>12</sup> Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan

<sup>13</sup> Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

<sup>14</sup> Division of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan

<sup>15</sup> Department of Hematology, Chiba University Hospital, Chiba, Japan

<sup>16</sup> Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

<sup>17</sup> Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan

<sup>18</sup> National Hospital Organization Nagoya Medical Center, Nagoya, Japan

<sup>19</sup> Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan

<sup>20</sup> Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

\*These authors contributed equally to this work.

**Running head:** *ASXL2* and *ZBTB7A* mutations in CBF-AML

**Corresponding author:** Hitoshi Kiyoi

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.

Phone: +81-52-744-2136

Fax: +81-52-744-2157

E-mail: [kiyoi@med.nagoya-u.ac.jp](mailto:kiyoi@med.nagoya-u.ac.jp)

## Abstract

We analyzed the clinical significance and genetic features of *ASXL2* and *ZBTB7A* mutations, and the alternatively spliced isoform of the *RUNX1-RUNX1T1* transcript, which is also called *AML1-ETO9a* (AE9a), in Japanese CBF-AML patients enrolled in the JALSG AML201 study. *ASXL2* and *ZBTB7A* genes were sequenced using bone marrow samples of 41 AML patients with t(8;21) and 14 with inv(16). The relative expression levels of AE9a were quantified using the real-time PCR assay in 23 AML patients with t(8;21). We identified *ASXL2* (34.1%) and *ZBTB7A* (9.8%) mutations in only AML patients with t(8;21). *ASXL2*-mutated patients had a significantly higher WBC count at diagnosis ( $P=0.04$ ) and a lower frequency of sex chromosome loss than wild-type patients (33 vs. 76%, respectively,  $P=0.01$ ). *KIT* mutations were the most frequently accompanied with both *ASXL2* (36%) and *ZBTB7A* (75%) mutations. Neither *ASXL2* nor *ZBTB7A* mutations had an impact on overall or event-free survival. Patients harboring cohesin complex gene mutations expressed significantly higher levels of AE9a than unmutated patients ( $P=0.03$ ). In conclusion, *ASXL2* and *ZBTB7A* mutations were frequently identified in Japanese AML patients with t(8;21), but not in those with inv(16). Further analysis is required to clarify the detailed biological mechanism of AE9a regulation of the cohesin complex.

## Keywords

Acute myeloid leukemia; core-binding factor; *ASXL1/2*; *ZBTB7A*;

*RUNX1-RUX1T1* transcript

## Introduction

Core-binding factor (CBF)-acute myeloid leukemia (AML) accounts for about 25% of Japanese adult AML patients, who are categorized as a favorable risk group; however, relapse occurs in approximately half of the patients [1]. Chromosomal aberrations  $t(8;21)(q22;q22)$  and  $inv(16)(p13.1q22)/t(16;16)(p13.1;q22)$  result in fusion transcripts encoding subunits of CBF [2]. Their fusion proteins, RUNX1-RUNX1T1 and CBFB-MYH11, reportedly block myeloid maturation, but are not sufficient to induce leukemia [3,4]. Additional driver mutations are, therefore, required for the clonal expansion of leukemia cells. *KIT* mutation is the most frequently identified driver mutation in CBF-AML, and it has been suggested to be a poor prognostic factor [5]. Recently, recurrent *ASXL1* or *ASXL2* (additional sex combs-like 1 or 2, respectively) and *ZBTB7A* (zinc finger and BTB domain containing 7A) mutations in AML patients with  $t(8;21)$  were identified. *ASXL1* and *ASXL2* are epigenetic regulators involved in the regulation or recruitment of the polycomb-group repressor complex and trithorax-group activator complex, and the loss of *ASXL2* promoted AML in association with  $t(8;21)$  [6,7]. *ASXL1* and *ASXL2* mutations were exclusively identified with an incidence of 12-19% and 17-23% in AML patients with  $t(8;21)$ , respectively [8-13]. *ZBTB7A* is known as a leukemia/lymphoma-related factor (LRF) that encodes a transcription factor of the POK (poxvirus and zinc finger and Krüppel)/ZBTB (zinc finger and broad complex, tramtrack, and bric-a-brac) family [14]. *ZBTB7A* mutations were identified in 10-23% of AML patients with  $t(8;21)$ , and commonly consisted of

missense or truncating mutations, resulting in alteration of the DNA binding ability of the zinc finger domains [15,12,16]. It has been reported that loss of *ZBTB7A* was associated with the up-regulation of glycolysis metabolism and tumor cell proliferation [17]. These results indicate that *ASXL1/2* and *ZBTB7A* mutations are closely associated with the development of CBF-AML, whereas their prognostic significance has not been clarified yet.

In addition, it has been reported that an alternatively spliced isoform of the *RUNX1-RUNX1T1* (also called *AML1-ETO*: AE) transcript, *RUNX1-RUNX1T19a* (also called *AML1-ETO9a*: AE9a), which encodes a C-terminally truncated *RUNX1-RUNX1T1* protein, might be associated with the development of AML with t(8;21) [18]. Coexpression of AE and AE9a is shown to block myeloid cell differentiation and reduce the latency of AML development in murine models. However, the clinical significance and genetic mechanism of AE9a expression remain unclear.

In the present study, we focused on the clinical and genetic features of CBF-AML harboring *ASXL2* and *ZBTB7A* mutations, and the AE9a expression level of t(8;21) AML in Japanese patients enrolled in the JALSG AML201 study.

## **Patients and methods**

### **Patients and treatment**

The JALSG AML201 study was a multi-center phase 3 randomized study for newly diagnosed *de novo* adult AML patients, except for those with acute promyelocytic leukemia (UMIN Clinical Trials Registry C000000157, <http://www.umin.ac.jp/ctrj/>). The patients were prospectively registered and randomly assigned to receive either idarubicin (IDR) or high-dose daunorubicin (HiDNR) for induction therapy, and those who achieved CR were again randomized to receive either four courses of conventional consolidation therapy or three courses of high-dose cytarabine (HiDAC) therapy. The AML201 study included 247 CBF-AML patients, of whom 55 patients' samples were available for comprehensive genetic analysis, and their clinical and genetic data were used for this study. This study was approved by the institutional review board of each participating institution and all patients provided informed consent for banking and molecular analysis before registration in accordance with the Declaration of Helsinki.

### **Mutation analysis**

In the previous study, comprehensive genetic analysis targeting 51 genes was performed, but it did not include *ASXL2* and *ZBTB7A* genes [19]. We, thus, additionally analyzed their mutations in this study. Exons 12 and 13 of *ASXL2*

and exons 2 and 3 of *ZBTB7A* genes were amplified using each forward and reverse primer set (Supplementary Table 1). Amplified products were purified using the MinElute 96 UF PCR Purification kit (Qiagen, Hilden, Germany), and sequenced on an ABI 3100 Avant sequence detection system (Applied Biosystems, Foster City, CA). Cytogenetic G-banding analysis was performed using standard methods. In addition, we also examined *RUNX1-RUNX1T1* and *CBFB-MYH11* chimeric gene transcripts by reverse transcriptase-mediated quantitative PCR (RQ-PCR), as previously reported [20].

#### **Quantification of *RUNX1-RUNX1T1* (AE) and *RUNX1-RUNX1T19a* (AE9a) mRNA expressions**

Complementary DNA (cDNA) was generated from total RNA using the SuperScriptII Reverse Transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The AE fusion transcript was amplified by nested PCR using the previously described primers (Supplementary Table 2) and AccuTaq LA DNA Polymerase (Sigma-Aldrich, St Louis, MO, USA) for 25 cycles in a volume of 50  $\mu$ L with an initial denaturation step of 98°C for 30 sec followed by 25 cycles of denaturation at 94°C for 15 sec, annealing at 58°C for 20 sec, extension at 68°C for 3 min, and with a final extension cycle of 68°C for 10 min [18]. To quantify the relative expression level of AE9a, the real-time quantitative (RQ)-PCR assay was performed in a total reaction mixture (20  $\mu$ L) containing 2  $\mu$ L of amplified AE fusion transcript, 10  $\mu$ L of 2 $\times$  TaqMan Universal Master Mix II with UNG (Applied Biosystems), forward and reverse primers, and



each probe (Supplementary Table 2). *GAPDH* was quantified as the internal control using TaqMan Gene Expression Master Mix (Applied Biosystems). RQ-PCR was performed with Applied Biosystems 7300 Real-time PCR System (Applied Biosystems) using the following protocol: an initial denaturation and polymerase activation step for 2 min at 50°C and 10 min at 95°C, followed by 45 cycles of denaturation at 95°C for 15 secs and 60°C for 1 min. Each RQ-PCR assay contained the dilution series of a standard for the calibration curve, and all samples and standards were run in duplicate. The standards were plasmid controls that contained the PCR products amplified by each primer set.

### **Statistical analysis**

Demographic factors and disease characteristics were compared using the standard  $\chi^2$  test for categorical data and the Mann–Whitney *U*-test for continuous variables. Probabilities of overall survival (OS) were estimated using the Kaplan-Meier method, and the log-rank test was used for univariate comparisons. The survival time was calculated from the date of entry into the JALSG AML201 study to death due to any cause or the last follow-up. Event-free survival (EFS) was defined as the time from the day of achieving CR to relapse, death due to any cause, or the last follow-up. Patients undergoing allogeneic stem cell transplantation were not censored at the time of transplantation. A significance level of  $P < 0.05$  was considered significant for all analyses. All statistical analyses were performed by Stata version 12 (Stata Corp., College Station, TX).

## Results

### Frequency and clinical features of *ASXL2* mutations in t(8;21) AML

We identified *ASXL2* mutations in 14 of 41 (34.1%) AML patients with t(8;21), but in no AML patients with inv(16). *ASXL2* mutations were preferentially identified in the 3' region of the gene with 13 frame-shift mutations and 1 single nucleotide variant mutation. Eight of 41 patients (19.5%) had *ASXL2* mutations in exon 12, whereas 6 of 41 (14.6%) had them in exon 13 (Figure 1). The characteristics of the AML patients with t(8;21) are summarized in Table 1. *ASXL2*-mutated patients had a significantly higher WBC count at the time of diagnosis than those with the wild-type (median: 12,400 vs. 7,100 cells/  $\mu$ L, respectively,  $P=0.04$ ). In cytogenetic analysis, the loss of sex chromosomes was observed in 4 (33%) *ASXL2*-mutated patients, with the rate being significantly lower than in wild-type patients (76%,  $P=0.01$ ). There was no difference in the frequency of del(9q) and no patient carried the trisomy 8 chromosome in our cohort.

The median follow-up period of survivors was 1,547 days (range, 1,002-2,355). *ASXL2* mutations had no impact on the CR rate ( $P=0.48$ ), OS ( $P=0.64$ , Figure 2A), or EFS ( $P=0.57$ , Figure 2B) compared with those with the wild-type, with a 3-year OS rate of 81.5% (95% confidence interval [CI], 61.1-91.8) vs. 71.4% (95%CI, 40.6-88.2) and with a 3-year EFS rate of 52.0% (95%CI, 31.3-69.2) vs. 66.7% (95%CI, 33.7-86.0), respectively (Table 1). Among 14 *ASXL2*-mutated patients, 12 achieved CR after induction therapy and received subsequent consolidation therapies (HiDAC group: 6, multiagent

chemotherapy group: 6). According to the consolidation treatment, there was no significant difference in OS ( $P=0.14$ ) or EFS ( $P=0.15$ ) in *ASXL2*-mutated patients.

### **Frequency and clinical features of *ZBTB7A* mutations in t(8;21) AML**

*ZBTB7A* mutations were identified in 4 of 41 (9.8%) AML patients with t(8;21), but none in AML patients with inv(16). Two of the 4 (50%) *ZBTB7A*-mutated patients had *ASXL2* mutations. Two had a frame-shift insertion resulting in the loss of the N-terminal BTB domain, one had a missense mutation resulting in an amino acid change, and the final one had a frameshift deletion resulting in alternation or loss of the C-terminal zinc-finger domain (Figure 1).

There was no significant difference in patients' age, sex, or additional cytogenetic abnormality according to *ZBTB7A* mutations (Table 1). The 3-year OS rates of *ZBTB7A*-mutated and -unmutated patients were 50.0% (95%CI, 5.8-84.5) and 81.1% (95%CI, 64.3-90.5), respectively, and 3-year EFS rates were 25.0% (95%CI, 8.9-66.5) and 60.6% (95%CI, 42.0-74.9), respectively; however, there was no significance in either OS ( $P=0.15$ , Figure 2C) or EFS ( $P=0.14$ , Figure 2D).

### **Cooperative gene mutations with *ASXL2* and *ZBTB7A***

Cooperative gene mutations accompanied by *ASXL2* and *ZBTB7A* mutations are shown in Table 1, Table 2, and Figure 3 [21]. *KIT* mutations were the most

frequently observed in both *ASXL2* and *ZBTB7A* mutations with frequencies of 36 and 75%, respectively. There was no significant correlation of *ASXL2* and *ZBTB7A* mutations with *KIT*, *FLT3*, and *NRAS*, which are frequently observed driver mutations in CBF-AML (Table 1). Within the 51 gene variants screened by target sequencing, chromatin modifier genes were significantly accumulated in *ASXL2*-mutated patients compared with those with wild-type ( $P=0.02$ ). *ASXL2* mutations were exclusive with *ASXL1* mutations. There was no significant correlation between other evaluated gene mutation families (Table 2). On the other hand, there was no significantly accumulated gene mutation accompanied by *ZBTB7A* mutation.

#### **Clinical features and outcomes according to the expression level of *RUNX1-RUNX1T19a* (*AE9a*)**

Quantitative analysis of *AE9a* expression was performed in 23 AML patients with t(8;21). The *AE9a* transcript was detected in 18 of 23 patients (85.7%). The median relative expression level of *AE9a* to *GAPDH* was 0.15 (range, 0-31.6). The patients were divided into two groups on the basis of a nearly bimodal distribution of relative *AE9a* expression to *GAPDH* ( $P=0.0001$ , Figure 4A). Therefore, a relative *AE9a* expression level of 0.5 was defined as the cut-off value. Nine patients who presented with higher relative amounts of *AE9a* to *GAPDH* than 0.5 ( $0.88 \pm 10.15$ ) were referred to as a High-*AE9a* group, whereas 14 who expressed lower relative amounts of *AE9a* to *GAPDH* than 0.5 ( $0.05 \pm 0.07$ ) were referred to as a Low-*AE9a* group. There was no difference in the

patient age ( $P=0.30$ ) or WBC count ( $P=0.28$ ) between these groups; however, more patients in High-*AE9a* group carried additional cytogenetic abnormalities, including the loss of sex chromosomes and del(9q) (Supplementary Table 3). The median follow-up period of survivors was 1,008 days (range, 274-2,150). The relative expression level of *AE9a* had no impact on the CR rate ( $P=0.24$ ), cycles of induction therapy ( $P=0.25$ ), OS ( $P=0.26$ ), or EFS ( $P=0.12$ ).

### **Correlation between *RUNX1-RUNX1T19a* (*AE9a*) expression level and gene mutations**

The relative expression level of *AE9a* was analyzed in 23 patients according to the gene mutation families listed in Table 2. *AE9a* expression levels of the patients harboring mutations in cohesin complex genes (*RAD21*, *SMC1A*, *SMC3*, and *STAG2*) were significantly higher than those in unmutated patients (0.08 vs. 1.78, respectively,  $P=0.03$ ). However, median relative *AE9a* expression levels were similar between wild-type and mutated patients in activating kinase (0.08 vs. 0.24, respectively,  $P=0.61$ ), chromatin modifiers (0.16 vs. 0.13, respectively,  $P=0.74$ ), transcription factors (0.16 vs. 0.07, respectively,  $P=0.33$ ), DNA methylation (0.16 vs. 0.08, respectively,  $P=0.44$ ), tumor suppressor families (0.16 vs. 0.03, respectively,  $P=0.37$ ), *KIT* (0.10 vs. 0.60, respectively,  $P=0.33$ ), and *ASXL2* (0.39 vs. 0.06, respectively,  $P=0.18$ ) genes (Figure 4B).

## Discussion

In this study, we analyzed the clinical characteristics and overlap mutations of the recently identified *ASXL2* and *ZBTB7A* mutations in Japanese CBF-AML patients. Consistent with previous reports, both mutations were identified in AML patients with t(8;21), but not in AML patients with inv(16). *ASXL2* mutations were more frequently observed in Japanese patients (34.1%) than in previous reports (16.7-22.7%) [11-13]. *ASXL2* mutation was significantly correlated with higher WBC counts at diagnosis, as previously reported [11]. In cytogenetics, it has been reported that *ASXL1* and *ASXL2* mutations were significantly correlated with del(9q) [13], whereas such a correlation was not observed in our patients; however, those mutations were negatively associated with the loss of sex chromosomes in our patients. Cooperative driver gene mutations including *KIT*, *FLT3*, and *NRAS* are frequently identified in AML patients with t(8;21). However, they did not show an association with either *ASXL2* or *ZBTB7A* mutations in this study. Although other mutations in chromatin modifier genes were frequently accompanied with *ASXL2* mutations in our cohort, *ASXL1* and *ASXL2* mutations were mutually exclusive, as previously reported, indicating a shared mechanism of transformation for mutations in these genes [11].

Consistent with a previous report, *ASXL2* mutations did not influence OS or EFS [13]. In the present study, we could not find clinical impacts of *ZBTB7A* mutations on OS and EFS. Further study in a large cohort is required to evaluate the prognostic impact of *ZBTB7A* mutation on the long-term prognosis.

We also analyzed the correlation between *AE9a* expression and genetic alterations. Although a previous report suggested that stimulated cell cycle progression under high *AE9a* expression increased the WBC count, WBC counts at diagnosis were similar between groups with high and low expression levels of *AE9a* [22]. Furthermore, regardless of any threshold setting, there were no correlations between the expression level of *AE9a* and prognosis or *KIT* mutation, as previously described [22]. Interestingly, high expression of *AE9a* was observed in patients harboring mutations in cohesin complex genes. The cohesin complex regulates chromosome segregation during meiosis and mitosis, which is essential for cell division [23]. Furthermore, it has been reported that cohesin complex gene mutations were rarely identified in founding clones, and likely represent secondary events in the clonal hierarchy and contribute to clonal transformation [24]. Therefore, C-terminally truncated RUNX1-RUNX1T1 (*AE9a*) might contribute to AML development by cooperating with the loss of function of cohesin complexes, resulting in rapid disease progression. Further analysis is required to clarify the detailed biological mechanism in *AE9a* regulation of the cohesin complex.

As our analysis included a limited number of patients, these findings need to be further evaluated in a larger scale cohort to further our understanding of the pathogenesis of AML with t(8;21).

**Funding information** This study was supported by Grants-in-Aid from the Scientific Research Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (17K09921), and from the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and

Development, AMED (17ck0106251).

## **Compliance with ethical standards**

**Conflicts of interest** H. Kiyoi received research funding from Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc. and Celgene Corporation, consulting fees from Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd., and honoraria from Bristol-Myers Squibb and Pfizer Japan Inc., N.A. received research funding from Chugai Pharmaceutical Co., Ltd. and Astellas Pharma Inc., S.M. received honoraria from Astellas Pharma Inc. and Otsuka Pharmaceutical Co., Ltd., N.U. received research funding from Nippon Shinyaku Pharmaceutical Co., Ltd., Novartis Pharma, Bristol-Myers Squibb, Celgene Corporation, Fujimoto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Sysmex Co., Ltd., consulting fees from Celgene Corporation, Fujimoto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Sysmex Co., Ltd., Astellas Pharma Inc., CIMIC Co., Ltd., Eli Lilly Japan, Huya Bioscience International, Janssen Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., SymBio Pharmaceuticals Co., Ltd., Takeda Bio Development Center Ltd. and Zenyaku Kogyo Co., Ltd., and honoraria from Bristol-Myers Squibb, Celgene Co., Ltd., Pfizer Japan Inc., Sysmex Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. AT received research funding from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc. and Takeda Pharmaceutical Co Ltd. T.N. received research funding from FUJIFILM Corporation, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd., patents and royalties from FUJIFILM Corporation, and honoraria from Nippon Boehringer Ingelheim Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., and I.M. received honoraria from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Kyowa Hakko Kirin Co., Ltd. The other authors have no relevant conflicts to disclose.



**Ethical approval** This study was approved by the institutional review board of each participating institution. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

## Figure legends

### **Figure 1. Schematic representation of *ASXL2* and *ZBTB7A* mutations.**

ASXN, Asx homology N; PHD, Plant homeodomain; BTB, BR-C ttk and bab; NLS, nuclear localization sequence; Zf, zincfinger.

### **Figure 2. Outcomes according to *ASXL2* and *ZBTB7A* mutations in t(8;21) AML.**

**a** Overall survival and **b** Event-free survival according to *ASXL2* mutations. **c** Overall survival and **d** Event-free survival according to *ZBTB7A* mutations.

### **Figure 3. Coorprative mutations with *ASXL2* and *ZBTB7A*.**

Circos plot of mutated genes according to the gene mutation families are shown.

### **Figure 4. Relative quantification of *AE9a* expression.**

**a** The relative expression level of *AE9a* in each patient and median values are shown. The cut-off value (0.5) of High- and Low-*AE9a* groups is shown in a dashed line.

**b** The relative expression level of *AE9a* according to gene mutation families and median values are shown.

## References

1. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. *Blood* 117 (8):2366-2372. doi:10.1182/blood-2010-07-295279
2. de Bruijn MF, Speck NA (2004) Core-binding factors in hematopoiesis and immune function. *Oncogene* 23 (24):4238-4248. doi:10.1038/sj.onc.1207763
3. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, Owens J, Eckhaus M, Bodine D, Liu PP (1999) The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. *Nat Genet* 23 (2):144-146. doi:10.1038/13776
4. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. *Proc Natl Acad Sci U S A* 98 (18):10398-10403. doi:10.1073/pnas.171321298
5. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. *J Clin Oncol* 24 (24):3904-3911. doi:10.1200/jco.2006.06.9500
6. Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O (2017) ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in

leukemia. Nat Commun 8:15429. doi:10.1038/ncomms15429

7. Li J, He F, Zhang P, Chen S, Shi H, Sun Y, Guo Y, Yang H, Man N, Greenblatt S, Li Z, Guo Z, Zhou Y, Wang L, Morey L, Williams S, Chen X, Wang QT, Nimer SD, Yu P, Wang QF, Xu M, Yang FC (2017) Loss of Asxl2 leads to myeloid malignancies in mice. Nat Commun 8:15456. doi:10.1038/ncomms15456
8. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2010) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 116 (20):4086-4094. doi:10.1182/blood-2010-05-283291
9. Boultonwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, Jadersten M, Killick S, Hellstrom-Lindberg E, Cazzola M, Wainscoat JS (2010) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24 (5):1062-1065. doi:10.1038/leu.2010.20
10. Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S (2014) High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia 28 (7):1449-1458. doi:10.1038/leu.2014.4
11. Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E (2014) Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood 124 (9):1445-1449. doi:10.1182/blood-2014-04-571018
12. Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z,

- Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Dohner K, Dohner H, Bullinger L, Zhang J, Kline JM, Downing JR (2016) The genomic landscape of core-binding factor acute myeloid leukemias. *Nat Genet* 48 (12):1551-1556. doi:10.1038/ng.3709
13. Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Gohring G, Kundgen A, Fiedler W, Wattad M, Held G, Kohne CH, Horst HA, Lubbert M, Ganser A, Schlenk RF, Dohner H, Dohner K, Paschka P (2017) Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. *Leukemia* 31 (4):1012-1015. doi:10.1038/leu.2017.18
  14. Lunardi A, Guarnerio J, Wang G, Maeda T, Pandolfi PP (2013) Role of LRF/Pokemon in lineage fate decisions. *Blood* 121 (15):2845-2853. doi:10.1182/blood-2012-11-292037
  15. Hartmann L, Dutta S, Opatz S, Vosberg S, Reiter K, Leubolt G, Metzeler KH, Herold T, Bamopoulos SA, Braundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Hopfner KP, Graf A, Krebs S, Blum H, Middeke JM, Stolz F, Thiede C, Wolf S, Bohlander SK, Preiss C, Chen-Wichmann L, Wichmann C, Sauerland MC, Buchner T, Berdel WE, Wormann BJ, Braess J, Hiddemann W, Spiekermann K, Greif PA (2016) ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. *Nat Commun* 7:11733. doi:10.1038/ncomms11733
  16. Lavalley VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hebert J (2016) RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. *Blood* 127 (20):2498-2501. doi:10.1182/blood-2016-03-703868
  17. Liu XS, Haines JE, Mehanna EK, Genet MD, Ben-Sahra I, Asara JM, Manning BD, Yuan ZM (2014) ZBTB7A acts as a tumor suppressor through

- the transcriptional repression of glycolysis. *Genes Dev* 28 (17):1917-1928. doi:10.1101/gad.245910.114
18. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. *Nat Med* 12 (8):945-949. doi:10.1038/nm1443
  19. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T (2014) Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. *Leukemia* 28 (8):1586-1595. doi:10.1038/leu.2014.55
  20. Osumi K, Fukui T, Kiyoi H, Kasai M, Koderia Y, Kudo K, Kato K, Matsuyama T, Naito K, Tanimoto M, Hirai H, Saito H, Ohno R, Naoe T (2002) Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. *Leuk Lymphoma* 43 (12):2291-2299. doi:10.1080/1042819021000040206
  21. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA (2009) Circos: an information aesthetic for comparative genomics. *Genome Res* 19 (9):1639-1645. doi:10.1101/gr.092759.109
  22. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B, Shi JY, Wang YY, Wang JH, Chen Y, Li JM, Gu LJ, Tang JY, Shen ZX, Gu BW, Zhao WL, Chen Z, Chen SJ (2009) AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. *Leukemia* 23 (9):1598-1604. doi:10.1038/leu.2009.104
  23. Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ, Kirchner A, Huang L, Chaturvedi A, Wichmann M, Wiehlmann L, Shahswar R, Damm F, Gohring G, Schlegelberger B, Schlenk R, Dohner K, Dohner H, Krauter J, Ganser A, Heuser M (2014) Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. *Blood* 123 (6):914-920. doi:10.1182/blood-2013-07-518746

24. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, Maciejewski JP (2014) Genetic alterations of the cohesin complex genes in myeloid malignancies. *Blood* 124 (11):1790-1798. doi:10.1182/blood-2014-04-567057

**Table 1. Patient characteristics**

	All patients (n=41)	ASXL2 wild (n=27)	ASXL2 mutation (n=14)	<i>P</i> -value*	ZBTB7A wild (n=37)	ZBTB7A mutation (n=4)	<i>P</i> -value†
<b>Age (yrs)</b>				0.25			0.92
10-19	3	2	1		3	0	
20-29	5	2	3		4	1	
30-39	10	10	0		9	1	
40-49	7	4	3		6	1	
50-59	14	8	6		13	1	
60-65	2	1	1		2	0	0.74
WBC (×10 <sup>3</sup> /μL), median [range]	9.5 [0.2-67.6]	7.1 [0.2-51.4]	12.4 [1.2-67.6]	0.04	8.8 [0.2-57.6]	16.4 [8.3-51.4]	0.18
<b>Additional cytogenetic abnormalities‡</b>							
-X or -Y	23 (62%)	19 (76%)	4 (33%)	0.01	20 (54%)	3 (75%)	0.56
del(9q)	4 (10%)	3 (11%)	1 (7%)	0.73	4 (11%)	0 (0%)	0.46
<b>Gene mutations</b>							
<i>KIT</i>	19 (46%)	14 (52%)	5 (36%)	0.33	16 (43%)	3 (75%)	0.55
exon 8	4 (10%)	2 (7%)	2 (14%)	0.48	3 (8%)	1 (25%)	0.28
exon 10-11	1 (2%)	1 (4%)	0 (0%)	0.47	1 (3%)	0 (0%)	0.74



exon 17	14 (34%)	11 (41%)	3 (21%)	0.22	12 (32%)	2 (50%)	0.48
<i>FLT3</i>	3 (7%)	2 (7%)	1 (7%)	0.98	4 (11%)	0 (0%)	0.49
ITD	2 (5%)	2 (7%)	0 (0%)	0.30	3 (8%)	0 (0%)	0.55
KDM	1 (2%)	0 (0%)	1 (7%)	0.26	1 (3%)	0 (0%)	0.74
<i>NRAS</i>	2 (5%)	1 (4%)	1 (7%)	0.63	1 (3%)	1 (25%)	0.05
<b>Outcomes</b>							
CR (%)	37 (90%)	25 (93%)	12 (86%)	0.48	33 (89%)	4 (100%)	0.49
3-year OS, % [95% CI]	78.1 [62.1-87.9]	81.5 [61.1-91.8]	71.4 [40.6-88.2]	0.64	81.1 [64.4-90.5]	50.0 [5.8-84.5]	0.15
3-year EFS, % [95% CI]	56.8 [39.4-70.8]	52.0 [31.3-69.2]	66.7 [33.7-86.0]	0.57	60.6 [42.0-74.9]	25.0 [0.9-66.5]	0.14


\*P value comparing *ASXL2* mutation versus wild patients. †P value comparing *ZBTB7A* mutation versus wild patients. ‡Data only available in 37 patients.

**Table 2. Cooperative gene mutations**

Gene	All patients	ASXL2		P-value*	ZBTB7A		P-value†
		wild	mutation		wild	mutation	
	(n=41)	(n=27)	(n=14)		(n=37)	(n=4)	
<b>Activating kinase</b>	26	18	8	0.55	22	4	0.11
<i>FLT3, KIT, NRAS, KRAS, CBL, JAK1, JAK3, PTPN11</i>	(63%)	(67%)	(57%)		(59%)	(100%)	
<b>Chromatin modifier</b>	11	4	7	0.02	9	2	0.27
<i>ASXL1, ATRX, BCOR, BCORL1, EZH2, KDM6A</i>	(27%)	(15%)	(50%)		(24%)	(50%)	
<b>Transcription factor</b>	6	3	3	0.38	6	(0%)	0.38
<i>ETV6, GATA2, MLL, NCOR1, NCOR2, RUNX1</i>	(15%)	(11%)	(21%)		(16%)		
<b>Cohesin</b>	7	4	3	0.60	7	0	0.34
<i>RAD21, SMC1A, SMC3, STAG2</i>	(17%)	(15%)	(21%)		(19%)	(0%)	
<b>DNA methylation</b>	5	3	2	0.77	5	0	0.43
<i>DNMT3A, DOT1L, IDH1, IDH2, TET2</i>	(12%)	(11%)	(14%)		(14%)	(0%)	
<b>Tumor suppressor</b>	9	4	5	0.13	7	2	0.15
<i>WT1, TP53, NOTCH1, NOTCH2, PBRM1, PHF6, EPB41L5</i>	(22%)	(15%)	(36%)		(19%)	(50%)	
<b>Spliceosome</b>	1	1	0	0.47	1	0	0.74
<i>SF3B1, SRSF2, ZRSR2, U2AF1</i>	(2.4%)	(4%)	(0%)		(3%)	(0%)	


\*P value comparing ASXL2 mutation versus wild patients. †P value comparing ZBTB7A mutation versus wild patients.

FIGURE 1




**FIGURE 2**


**A**



**B**



**C**



**D**




FIGURE 3






FIGURE 4

A



B



# Supplementary Table 1.

## Primer sequences for Sanger sequencing of *ASXL2* and *ZBTB7A*

ASXL2				
Region	PCR amplification and sequencing primers			
Exon12-1	forward	CGGTAGGTATCAGAGCCAGA		
	reverse	TCCTCATCCTTTGGGCACTT		
Exon12-2	forward	TCTCCACATCTTCAGAGCCC		
	reverse	ACATAGGGTTCAGACGATCTCT		
Exon13-1	forward	GTGGATGCAAGGACCCTAGA		
	reverse	GGGTTTGCTGTAGTTGTGCT		
Exon13-2	forward	GTCTGAGACCAAGACCACCC		
	reverse	GCAGTCAGTGAACCGTTTT		
Exon13-3	forward	CCCCAGGTCAGTGCAACTA		
	reverse	ACCTGAGTGAGCGAAGTTGA		
Exon13-4	forward	CCAGCATTGACACACACCAA		
	reverse	TTGCCTTACCTCTCACTGCA		
Exon13-5	forward	TGAAAAGACCCTAGCCAGAGA		
	reverse	TGTGATTCCAAAAGGACGCA		
ZBTB7A				
Region	PCR amplification primers		Sequencing primers	
Exon2-1	forward	AACGCTGCTTCTCAAGGGCC	forward	AACGCTGCTTCTCAAGGGCC
	reverse	ACGGCCTCCTTGGTGGCAT	reverse	ACGGCCTCCTTGGTGGCAT
Exon2-2	forward	CGTGGGTGACATCCTCAGC	forward	CGTGGGTGACATCCTCAGC
	reverse	CGTGCGTGTATGTGTGCGTC	reverse	GACAGGAAGCCCGGAGAGT
Exon2-3	forward	CGTGGGTGACATCCTCAGC	forward	CACCGGGGGTCTCTTTCC
	reverse	CGTGCGTGTATGTGTGCGTC	reverse	CGTGCGTGTATGTGTGCGTC
Exon3-1	forward	AAGGGTGATGATCCAGGGCC	forward	AAGGGTGATGATCCAGGGCC
	reverse	TCTGTCTCTCTCTTTCTCGGG	reverse	TCTGTCTCTCTCTTTCTCGGG

**Supplementary Table 2.**

**Primer sequences for nested PCR of *RUNX1-RUNX1-T1* and real-time PCR of *AE* and *AE9a***

<b>Nested PCR</b>	
forward primer	5'- GAGGGAAAAGCTTCACTCTG - 3'
reverse primer	5'- TGGCGCTTCACCTCATT- 3'
<b>Real-time PCR for AE</b>	
forward primer	5'- AGAGTCCCGTCAACCCAGAC -3'
reverse primer	5'- ATCTCCTCTGGCACGTATCC -3'
probe	5'- 6FAM-CAGTTGCACTAGACGCGCATC -TAMRA-3'
<b>Real-time PCR for AE9a</b>	
forward primer	5'- TATATTGATGGCGGCCCTTG -3'
reverse primer	5'- ATCTCCTCTGGCACGTATCC -3'
probe	5'-6FAM-AATGGTCTCCATCCTGTACGCG-TAMRA-3'



**Supplementary Table 3.****Patient characteristics according to *AE9a* expression**

	<b>High-<i>AE9a</i></b> (n=9)	<b>Low-<i>AE9a</i></b> (n=14)	<b><i>P</i>-value</b>
Age (yrs), median [range]	39 [15-59]	49 [29-64]	0.30
WBC ( $\times 10^3/\mu\text{L}$ ), median [range]	6.9 [1.8-25.2]	11.3 [2.0-68.7]	0.28
<b>Additional cytogenetic abnormalities*</b>	8 / 8	7 / 12	0.04
-X or -Y	6 / 8	5 / 12	0.14
del (9q)	2 / 8	1 / 12	0.31
<b>Outcomes</b>			
CR	9 (100%)	12 (86%)	0.24
3-year overall survival, % [95% confidence interval]	80.0 [40.9-94.6]	64.3 [34.3-83.3]	0.26
3-year event free survival, % [95% confidence interval]	60.0 [25.3-82.7]	33.3 [10.3-58.8]	0.12

\*Data only available in 20 patients.